Last reviewed · How we verify

R-MP and Procarbazine maintenance — Competitive Intelligence Brief

R-MP and Procarbazine maintenance (R-MP and Procarbazine maintenance) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Alkylating agent. Area: Oncology.

phase 3 Alkylating agent Oncology Small molecule Live · refreshed every 30 min

Target snapshot

R-MP and Procarbazine maintenance (R-MP and Procarbazine maintenance) — University Hospital Freiburg. R-MP and Procarbazine work together to target and kill cancer cells through a combination of DNA damage and inhibition of DNA repair.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
R-MP and Procarbazine maintenance TARGET R-MP and Procarbazine maintenance University Hospital Freiburg phase 3 Alkylating agent
Paraplatin Carboplatin MYLAN SEIYAKU Ltd marketed Platinum-containing alkylating agent DNA 1989-01-01
Cytoxan (Lyophilized) cyclophosphamide Baxter marketed Alkylating agent Tumor cell DNA 1959-01-01
Cyclophosphamide and glucocorticoids Cyclophosphamide and glucocorticoids Peking Union Medical College Hospital marketed Alkylating agent + corticosteroid combination
Trabectidin (Yondelis) Trabectidin (Yondelis) North Eastern German Society of Gynaecological Oncology marketed DNA-binding alkylating agent DNA (minor groove binder)
Platinum-Based Chemotherapy Platinum-Based Chemotherapy Genprex, Inc. marketed Platinum-based alkylating agent DNA
Cyclophosphamide (CYC) Cyclophosphamide (CYC) Hansa Biopharma AB marketed Alkylating agent DNA

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

Sponsor landscape (Alkylating agent class)

  1. Assistance Publique - Hôpitaux de Paris · 2 drugs in this class
  2. M.D. Anderson Cancer Center · 2 drugs in this class
  3. Nanfang Hospital, Southern Medical University · 2 drugs in this class
  4. Asahi Kasei Pharma Corporation · 1 drug in this class
  5. Baxter · 1 drug in this class
  6. BeBetter Med Inc · 1 drug in this class
  7. Astellas Pharma China, Inc. · 1 drug in this class
  8. Children's Cancer Group, China · 1 drug in this class
  9. Federal Research Institute of Pediatric Hematology, Oncology and Immunology · 1 drug in this class
  10. Celyad Oncology SA · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). R-MP and Procarbazine maintenance — Competitive Intelligence Brief. https://druglandscape.com/ci/r-mp-and-procarbazine-maintenance. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators: